A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

Recruiting now · Phase 1

Conditions studied: Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN), Extra-renal Lupus (ERL)

In brief

This Phase 1, open label, dose escalation study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of HB2198, a tetravalent bispecific anti CD19/CD20 antibody, in adults with moderately to severely active systemic lupus erythematosus (SLE), including lupus nephritis and extra renal lupus. Approximately 30 participants will receive two intravenous doses of HB2198 and be followed for 12 months to assess safety, B cell depletion, disease activity, immunologic biomarkers, and renal outcomes.

Key facts

Study ID

NCT07491900

Run by

Hinge Bio

People needed

30

Starts

2026-03-23

Expected to finish

2028-10-24

Last updated by the study team

2026-03-25

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• • Meet 2019 ACR / 2023 EULAR SLE classification criteria
• Moderate or high disease activity (SLEDAI 2K ≥6; PGA ≥1)
• LN participants: biopsy confirmed active Class III/IV ± V or Class V LN; proteinuria ≥0.8 g/g; eGFR ≥30 mL/min/1.73 m²
• ERL participants: inadequate response/intolerance to ≥1 standard SLE therapy
• Positive ANA (≥1:80) or SLE associated autoantibodies
• Required minimum lab values (lymphocytes ≥500/µL, B cells ≥25/µL, ANC ≥1000/mm³, IgG ≥600 mg/dL, etc.)
• Women of childbearing potential: negative pregnancy test; contraception required
• Voluntary informed consent

You may not qualify if…

• (Key) Inclusion Criteria:
• Meet 2019 ACR / 2023 EULAR SLE classification criteria
• Moderate or high disease activity (SLEDAI 2K ≥6; PGA ≥1)
• LN participants: biopsy confirmed active Class III/IV ± V or Class V LN; proteinuria ≥0.8 g/g; eGFR ≥30 mL/min/1.73 m²
• ERL participants: inadequate response/intolerance to ≥1 standard SLE therapy
• Positive ANA (≥1:80) or SLE associated autoantibodies
• Required minimum lab values (lymphocytes ≥500/µL, B cells ≥25/µL, ANC ≥1000/mm³, IgG ≥600 mg/dL, etc.)
• Women of childbearing potential: negative pregnancy test; contraception required
• Voluntary informed consent
• (Key) Exclusion Criteria:
• Anti CD19 or anti CD20 therapy within 6 months
• Active CNS lupus
• Significant cardiovascular, pulmonary, hepatic, or uncontrolled systemic disease
• Active infection or recent serious infection
• Positive HBV DNA or HCV RNA; HIV infection
• Major surgery within 4 weeks
• Prior organ or stem cell transplant
• Current pregnancy or breastfeeding
• Recent IVIg or plasmapheresis (<3 months)
• Live vaccine within 30 days
• Any condition judged unsuitable by Investigator

Where it is running

• Investigational site — Brisbane, Australia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.